Bone Biologics gets Nasdaq bid-price delisting notice; plans reverse split vote

Bone Biologics Corp

• Nasdaq notice on Sept 10, 2026: BBLG common stock bid price below $1 for 30 consecutive sessions, violating Rule 5550(a)(2).
• 180-day compliance period runs to March 9, 2027; can cure with 10 straight business days at $1.00 or higher.
• If not cured, may qualify for additional 180-day period if other listing standards met; otherwise delisting proceedings start.
• Company intends to seek stockholder approval for a reverse stock split at upcoming annual meeting to regain compliance.
• Notice has no immediate effect on Nasdaq listing; management monitoring bid price and evaluating options.